Poverty, prostitution, insecurity, and precarious living conditions are the hallmarks of the Pakadjuma neighborhood in Kinshasa. The insecurity in this neighborhood is compounded by extreme poverty, pushing many women to engage in survival activities, often at the expense of their health.
As climate change intensifies, its impact on sexual and reproductive health and rights (SRHR), is becoming increasingly concerning. However, there has been limited research on how this crisis specifically affects SRHR services and the health of vulnerable communities.
This year, over four billion people in more than 40 countries have already or will be going to the polls. As anti-rights groups intensify their efforts to roll back progress on gender justice, LGBTQ+ rights, and access to abortion and reproductive health care, the stakes have never been higher.
Ever since she was in college, Nisa Anisa, Ipas Indonesia’s climate change specialist, has been passionate about women’s issues.
Marking the 21st anniversary of the landmark Maputo Protocol, which guarantees extensive rights to African women and girls, Ipas hosted a two-day regional conference in Mozambique devoted to exploring the challenges and successes of implementing this fundamental treaty for gender equity.
Ipas board member David Imago-Jácome is a dedicated advocate for universal abortion access and SRHR. As the director of YIELD Hub, he empowers youth and champions their sexual and reproductive health rights. Here he shares his journey as a young advocate and what inspires him most about the next generation.
Ipas Nepal is collaborating with women and girls, local health officials and community partners to ensure access to reproductive health care after climate disasters.
Seeking to more effectively protect and promote abortion rights in Africa, Ipas and key partners have launched CATALYSTS—an ambitious, Africa-led coalition of abortion rights advocates.
Today’s dismissal offers only a delay to extremist politicians’ crusade to override the rights of pregnant people at all costs.
Today the U.S. Supreme Court rejected the anti-abortion case that sought to reverse the FDA’s approval of the medication abortion drug mifepristone—based on false claims that the drug is unsafe. The ruling ensures that mifepristone will remain available.